Delcath Systems, Inc.

410 articles with Delcath Systems, Inc.

• Delcath Systems Reports First Quarter 2022 Results and Provides Business Update

  5/10/2022

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2022.

• Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting

  5/9/2022

  Delcath Systems, Inc. announced the acceptance of a poster presentation at the upcoming American Society of Clinical Oncology 2022 Annual Meeting, to be held in-person on June 3-7, 2022, in Chicago, Illinois.

• Delcath Systems to Host First Quarter 2022 Results

  4/28/2022

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it will host a conference call on May 10, 2022, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2022.

• Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference

  4/8/2022

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate in the Canaccord Genuity Horizons in Oncology Conference.

• Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference

  3/29/2022

  Delcath Systems, Inc. announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference, via presentation and panel discussion.

• Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update

  3/25/2022

  Delcath Systems, Inc. today reported business highlights and financial results for the fourth quarter and full-year ended December 31, 2021.

• Delcath Systems to Host Fourth Quarter and Full Year 2021 Results

  3/15/2022

  Delcath Systems, Inc. announced it will host a conference call on March 25, 2022, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2021.

• Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe

  3/2/2022

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that on February 28 its CHEMOSAT Hepatic Delivery System received Medical Device Regulation (MDR) certification under the new European Medical Devices Regulation [2017/745/EU].

• Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®

  2/22/2022

  Delcath Systems, Inc. announced that effective March 1, 2022, it will resume direct responsibility for sales, marketing and distribution activities relating to the CHEMOSAT® Hepatic Delivery System in Europe.

• Delcath Systems to Present at Upcoming Virtual Investor Conferences - Feb 10, 2022

  2/10/2022

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that management will participate at these upcoming virtual investor conferences.

• Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported

  2/7/2022

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the Company has appointed Anthony Dias as its new Vice President of Finance.

• Results of Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System Published in Melanoma Research

  2/3/2022

  Delcath Systems, Inc. announces that results from a single-institution retrospective study, conducted by University Hospital Southampton NHS Foundation Trust (UHS) in England on the use of the Delcath CHEMOSAT® Hepatic Delivery System.

• Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022

  1/7/2022

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference.

• Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

  12/2/2021

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive results from the phase 3 FOCUS study.

• Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting

  11/30/2021

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd, from 10:00am ET – 1:30pm EST.

• Delcath Systems Announces Third Quarter 2021 Results

  11/9/2021

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, reported business highlights and financial results for the third quarter ended September 30, 2021.

• Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021

  11/8/2021

  Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference.

• Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021

  11/5/2021

  Delcath Systems, Inc. announced today it will host a comprehensive Investor Update event on Thursday, December 2 nd , from 10:00am ET – 1:00pm ET.

• Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results

  10/25/2021

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2021.

• Delcath Systems to Present at Upcoming Virtual Investor Conferences in September 2021

  9/2/2021

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it will participate in three upcoming conferences.